Psoriatic arthritis: trials for referral
136 open trials in the registries we read. Each row links to its registry record.
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Where the open trials are
Type a city to sort by distance. The distance is worked out in your browser; the city is not sent anywhere.
136 trials shown
Phase 165 sites
RecruitingBulgaria, Czechia, Germany, Poland, Slovakia, United States
NCT07290036
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
UCB Biopharma SRL
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingFrance
NCT07460739
Efficacy of a Self-Management Smartphone App to Improve Safety Skills in Patients With Inflammatory Arthritis
Assistance Publique - Hôpitaux de Paris
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 20 sites
Not yet recruiting
NCT07923773
Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension)
Novartis Pharmaceuticals
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 41 site
RecruitingUnited States
NCT07111494
Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial
Medical College of Wisconsin
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 37 sites
RecruitingSpain, Greece, Israel
NCT05767047
A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis
Amgen
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 377 sites
RecruitingArgentina, Austria, Australia, Belgium, Brazil, China
NCT03773965
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
Eli Lilly and Company
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 41 site
RecruitingUnited States
NCT07654751
A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically
Janssen Research & Development, LLC
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 358 sites
RecruitingArgentina, Australia, Belgium, Brazil, China, Germany
NCT06663332
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Janssen Research & Development, LLC
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 30 sites
Not yet recruiting
NCT07871721
A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt)
Takeda
Registry updated 27 Oct 2026
Registry record: ClinicalTrials.govPhase 323 sites
RecruitingCanada, Germany, Spain, France, United Kingdom, Poland
NCT06668181
An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
UCB Biopharma SRL
Registry updated 23 Oct 2026
Registry record: ClinicalTrials.govPhase 346 sites
RecruitingAustria, Belgium, Germany, Spain, France, United Kingdom
NCT04804553
Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
Amgen
Registry updated 20 Oct 2026 · The registries disagree on the status
Registry record: ClinicalTrials.govPhase 3187 sites
RecruitingBelgium, Bulgaria, Chile, Czechia, Germany, Estonia
NCT06671483
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
Takeda
Registry updated 14 Oct 2026 · The registries disagree on the status
Registry record: ClinicalTrials.govPhase 111 sites
RecruitingUnited States
NCT06751238
Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
Novartis Pharmaceuticals
Registry updated 13 Oct 2026
Registry record: ClinicalTrials.govPhase 23 sites
RecruitingUnited States
NCT07801495
A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis
Novartis Pharmaceuticals
Registry updated 13 Oct 2026
Registry record: ClinicalTrials.govPhase 20 sites
Not yet recruiting
NCT07869134
Phase 2 Trial of FT2109 for the Treatment of Psoriatic Arthritis
Forward Therapeutics
Registry updated 9 Oct 2026
Registry record: ClinicalTrials.govPhase 346 sites
RecruitingBulgaria, Brazil, China, Czechia, Germany, Spain
NCT06869551
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
Bristol-Myers Squibb
Registry updated 6 Oct 2026
Registry record: ClinicalTrials.govPhase 152 sites
RecruitingCanada, United States
NCT03816345
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
National Cancer Institute (NCI)
Registry updated 5 Oct 2026
Registry record: ClinicalTrials.govPhase 114 sites
RecruitingCanada, Switzerland, Germany, Spain, United States
NCT06888193
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
UCB Biopharma SRL
Registry updated 18 Sept 2026
Registry record: ClinicalTrials.govPhase 3163 sites
RecruitingAustralia, Belgium, Bulgaria, China, Czechia, Germany
NCT07286058
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
Takeda
Registry updated 9 Sept 2026
Registry record: ClinicalTrials.govPhase 317 sites
By invitation onlyUnited States
NCT07223138
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis
MoonLake Immunotherapeutics AG
Registry updated 9 Sept 2026
Registry record: ClinicalTrials.govNo phase1 site
Not yet recruitingEgypt
NCT07398651
Apremilast and Adalimumab in Psoriatic Arthritis Patients
Tanta University
Registry updated 8 Sept 2026
Registry record: ClinicalTrials.govPhase 30 sites
Not yet recruiting
NCT07791199
Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers
Bristol-Myers Squibb
Registry updated 3 Sept 2026
Registry record: ClinicalTrials.govPhase 243 sites
RecruitingChina
NCT07406035
A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Registry updated 2 Sept 2026
Registry record: ClinicalTrials.govPhase 41 site
RecruitingUnited States
NCT07280702
Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease
University of Texas Southwestern Medical Center
Registry updated 1 Sept 2026
Registry record: ClinicalTrials.govPhase 334 sites
RecruitingAustralia, Canada, Germany, Spain, France, United Kingdom
NCT06100744
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
AbbVie
Registry updated 1 Sept 2026
Registry record: ClinicalTrials.govPhase 411 sites
RecruitingIndia
NCT07141004
A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA)
Johnson & Johnson Private Limited
Registry updated 28 Aug 2026
Registry record: ClinicalTrials.govPhase 41 site
Not yet recruitingUnited States
NCT07744191
A Clinical Trial of Antiplatelets in Psoriasis
NYU Langone Health
Registry updated 5 Aug 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingFrance
NCT07718815
HLA B Leader in Patients With Psoriatic Arthritis
Centre Hospitalier Universitaire, Amiens
Registry updated 22 Jul 2026
Registry record: ClinicalTrials.govPhase 42 sites
RecruitingBrazil
NCT07087912
Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
University of Sao Paulo General Hospital
Registry updated 20 Jul 2026
Registry record: ClinicalTrials.govPhase 21 site
Not yet recruitingMexico
NCT07706530
Oral CBP-0276 or Placebo in Adults With Active Psoriatic Arthritis (PsA)
Clarent Biopharma, Inc.
Registry updated 16 Jul 2026
Registry record: ClinicalTrials.gov
The same sites as a list
- United States30 open trials
- France22 open trials
- Germany20 open trials
- Italy16 open trials
- Spain15 open trials
- Poland12 open trials
- China12 open trials
- United Kingdom11 open trials
- Canada11 open trials
- Czechia9 open trials
- Belgium9 open trials
- Türkiye8 open trials
- Bulgaria7 open trials
- Portugal7 open trials
- Egypt7 open trials
- Greece6 open trials
- Israel6 open trials
- Australia5 open trials
- South Korea5 open trials
- Hungary5 open trials
- Mexico4 open trials
- Brazil4 open trials
- Denmark4 open trials
- Norway4 open trials
- Taiwan4 open trials
- Sweden4 open trials
- Japan3 open trials
- Argentina3 open trials
- Austria3 open trials
- Romania3 open trials
- Netherlands3 open trials
- Estonia3 open trials
- Latvia3 open trials
- Puerto Rico3 open trials
- Slovakia2 open trials
- India2 open trials
- Lithuania2 open trials
- Croatia2 open trials
- New Zealand2 open trials
- Switzerland2 open trials
- Russia1 open trial
- South Africa1 open trial
- Chile1 open trial
- Hong Kong1 open trial
- Costa Rica1 open trial
- Saudi Arabia1 open trial
- Ireland1 open trial
Who treats this
Institutions with trials or publications in this disease (OpenAlex, registries). Institutions only, no people.
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino
Turin, Italy
1 trial · 9 publications · ROR
What changed in the last 7 days
Registry facts, one per line, newest first.
Opened for recruitment
Identification of Serum Level of Glutathione Peroxidase 4
NCT06554392 · No phase · Egypt
Source: ClinicalTrials.govClosed for recruitment
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
NCT05669833 · Phase 3 · United States
Source: ClinicalTrials.govOpened for recruitment
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
NCT06671483 · Phase 3 · Belgium, Bulgaria, Chile, Czechia, Germany, Estonia
Source: ClinicalTrials.govPhase changed: Phase 4 → Phase 3
NCT06506916 · Phase 3 · Germany, Poland, United States
Source: ClinicalTrials.govOpened for recruitment
Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
NCT04804553 · Phase 3 · Austria, Belgium, Germany, Spain, France, United Kingdom
Source: ClinicalTrials.govClosed for recruitment
NCT03671148 · Phase 3 · Argentina, Australia, Belgium, Brazil, Canada, Germany
Source: ClinicalTrials.govOpened for recruitment
NCT03671148 · Phase 3 · Argentina, Australia, Belgium, Brazil, Canada, Germany
Source: ClinicalTrials.govClosed for recruitment
Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
NCT04804553 · Phase 3 · Austria, Belgium, Germany, Spain, France, United Kingdom
Source: ClinicalTrials.govClosed for recruitment
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
NCT06671483 · Phase 3 · Belgium, Bulgaria, Chile, Czechia, Germany, Estonia
Source: ClinicalTrials.gov
Results card
Trials that finished or stopped in the last 3 years, with the reason the registry gives and linked publications.
No phaseEnded 16 Oct 2026
Completed603 participants
NCT05908240
Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis
Phase 3Ended 2 Jul 2026
Completed453 participants
NCT04936308
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
Phase 3Ended 23 Jun 2026
Completed48 participants
NCT05083182
A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis
No phaseEnded 11 Jun 2026
Phase 3Ended 3 Jun 2026
Completed553 participants
NCT06624228
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
Phase 3Ended 26 May 2026
Completed1131 participants
NCT04009499
A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
- Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies. · RMD open, 2026
- Bimekizumab efficacy across GRAPPA domains to 3 years in patients with psoriatic arthritis: a post hoc analysis of two phase 3 studies. · Rheumatology (Oxford, England), 2026
- Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studies. · Rheumatology (Oxford, England), 2026
No phaseEnded 14 May 2026
Completed302 participants
NCT06714461
A Study of the Effectiveness of Additional Risk Minimization Measures Related to ARAVA® (Leflunomide) in Saudi Arabia
Phase 3Ended 23 Apr 2026
Completed279 participants
NCT06588296
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
- Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial. · Arthritis & rheumatology (Hoboken, N.J.), 2026
Phase 1Ended 8 Apr 2026
Stopped early5 participants
NCT06522035
Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis
Reason given: reprioritization
No phaseEnded 5 Mar 2026
Completed6967 participants
NCT07580092
Construct Validity and Responsiveness of EQ-5D-3L and EQ-5D-5L in Patients With Inflammatory Joint Disease
No phaseEnded 2 Mar 2026
No phaseEnded 1 Mar 2026
Completed460 participants
NCT07277491
Assessment of Nutritional Status in Rheumatic Diseases and Association to Disease Activity
No phaseEnded 28 Feb 2026
No phaseEnded 6 Feb 2026
Completed101 participants
NCT05631223
Use of Telemedicine to Address 'Off Target' Symptoms in Psoriatic Arthritis (PsA)
No phaseEnded 5 Jan 2026
Completed16 participants
NCT06555562
Activating the Cholinergic Anti-Inflammatory Pathway in Healthy Volunteers and People With Inflammatory Arthritis
No phaseEnded Dec 2025
Withdrawn before start0 participants
NCT02450396
Pregnancy and Medically Assisted Conception in Rare Diseases
Reason given: Abandonment of the study project
No phaseEnded 31 Dec 2025
Completed70 participants
NCT07386717
Upadacitinib Versus IL-17 Inhibitors in Patients With Psoriatic Arthritis
No phaseEnded 31 Dec 2025
No phaseEnded 31 Dec 2025
No phaseEnded 31 Dec 2025
Completed26 participants
NCT05545839
Transition to Adulthood Through Coaching and Empowerment in Rheumatology
Show more
Phase 3Ended 22 Dec 2025
Completed508 participants
NCT04314544
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)
No phaseEnded 18 Dec 2025
Completed70 participants
NCT01969188
A Study of Novel Immune Modulating Biomarkers in Patients With Spondyloarthritis With Axial Involvement
No phaseEnded 11 Dec 2025
Completed60 participants
NCT05590247
Role of Intermittent Fasting in Psoriasis and Psoriatic Arthritis
Phase 4Ended 9 Dec 2025
Completed20 participants
2024-511401-40-00
Investigating the role of JAK inhibition in achieving and maintaining disease remission in psoriatic arthritis (PsA).
Phase 4Ended 8 Dec 2025
No phaseEnded 30 Nov 2025
Withdrawn before start0 participants
NCT07255781
Shared Pathways Between Non-Alcoholic Fatty Liver Disease and Psoriatic Disease With Guselekumab Therapy
Reason given: The sponsor determined that enrollment would not meet their expectations and decided to withdraw the study.
No phaseEnded 31 Oct 2025
Completed140706 participants
NCT05413044
A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) Register
No phaseEnded 31 Oct 2025
Completed38396 participants
NCT05421442
A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database
Phase 4Ended 30 Sept 2025
Completed24 participants
NCT05988684
Effect of Metformin on Carotid Atherosclerosis for Non-diabetic Patients With PsA (CAMPA Study)
No phaseEnded 2 Sept 2025
Completed33 participants
NCT06101706
Assessment of Fatigue in Psoriatic Arthritis and Cutaneous Psoriasis Patients
No phaseEnded 25 Aug 2025
No phaseEnded 20 Aug 2025
Completed127 participants
NCT05155098
2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis
Phase 1Ended 23 Jun 2025
Completed45 participants
NCT06191042
A Study to Evaluate the Safety and Tolerability, and the Efficacy of Si-544 in Adults With Psoriasis Vulgaris or Psoriatic Arthritis
No phaseEnded 13 Jun 2025
No phaseEnded 31 May 2025
Completed201 participants
NCT07054749
Artificial Intelligence Literacy and E-Health Literacy in Rheumatic Diseases
- Digital and artificial intelligence literacy in inflammatory rheumatic and degenerative joint diseases. · Advances in medical sciences, 2026
No phaseEnded 14 Apr 2025
Completed84 participants
NCT05571696
Mind Matters: A High Touch, Low Cost Approach to Improving Mental Health Outcomes in Patients With Psoriatic Diseases
Phase 3Ended 10 Apr 2025
Phase 4Ended 31 Mar 2025
Withdrawn before start0 participants
NCT04417114
SystemIc iNflammation and Microvascular diSease PreventIon in psoRiatic diseasE
Reason given: The study was not funded.
No phaseEnded 30 Mar 2025
Completed50 participants
NCT06729463
IKBKB Gene Polymorphism (Single Nucleotide Polymorphism) (SNP) in Psoriatic and Psoriatic Arthritis Patients
No phaseEnded 12 Feb 2025
Stopped early81 participants
NCT05447741
Quantitative Ultrasound of the Enthesis in Fibromyalgia and Psoriatic Arthritis
Reason given: The recruitment and examination of participants were halted prematurely due to depleted funds.
No phaseEnded 31 Jan 2025
Completed76 participants
NCT05128500
Follow-up Evaluating Clinical and Radiological Outcomes of Total Shoulder Arthroplasty With Permedica's MIRAI Prosthesis
Phase 4Ended 22 Jan 2025
Completed20 participants
2024-512669-15-00
U3P study - Upadacitinib in Psoriatic Arthritis Pain Processing
No phaseEnded Dec 2024
Paused60 participants
NCT04065958
Yoga-mindfulness for Pain Management in Inflammatory Arthritis
Reason given: 1st: Covid-19 pandemic. 2nd: Lack of resources
No phaseEnded 31 Dec 2024
Completed446 participants
NCT03531073
Multicentre ObservatioNal Initiative in Treat to Target Outcomes in Psoriatic Arthritis
No phaseEnded 16 Dec 2024
No phaseEnded 25 Nov 2024
Phase 3Ended 7 Nov 2024
Completed55 participants
NCT03769168
An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)
Phase 4Ended 31 Oct 2024
Completed192 participants
NCT03739853
Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial
Phase 3Ended 22 Oct 2024
Completed119 participants
NCT04632927
Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment
Phase 2/3Ended 3 Oct 2024
Completed78 participants
2022-501362-22-00
A study to test if izokibep improves psoriatic arthritis symptoms and to see how safe izokibep is
Phase 3Ended 30 Sept 2024
No phaseEnded 30 Sept 2024
Completed77651 participants
NCT06568029
Construct Validity and Responsiveness of EQ-5D-3L in Patients With Rheumatic Disease
No phaseEnded 30 Sept 2024
Completed66 participants
NCT07169682
Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients With Psoriasis
No phaseEnded 28 Sept 2024
Completed36 participants
NCT05215561
Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPP
Phase 4Ended 23 Sept 2024
Completed250 participants
NCT05855967
A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India
Phase 3Ended 9 Sept 2024
No phaseEnded 15 Aug 2024
Phase 2/3Ended 8 Aug 2024
Stopped early351 participants
NCT05623345
Psoriatic Arthritis Study of Izokibep
Reason given: Per our 13Aug24 press release, we announced discontinuation of internal development in this indication. This decision was not due to safety reasons.
Phase 2Ended 6 Aug 2024
Completed91 participants
NCT05071664
A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis
No phaseEnded 30 Jul 2024
Completed116 participants
NCT04517669
Effectiveness of Treatment With Tofacitinib in Patients With Psoriatic Arthritis in Routine Clinical Practice
Not medical advice. fetched 10 Nov 2026